Adult medulloblastoma, from spongioblastoma cerebelli to the present day

A review of treatment and the integration of molecular markers

Nicole A Shonka, Alba Brandes, John F. de Groot

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Although they represent the most common malignant brain tumor in the pediatric population, medulloblastomas are rare in adults, with an incidence of 0.5 per million. With only one exception, all of the prospective clinical trials in this disease have been done in the pediatric population, and therefore therapy for adult medulloblastoma has been either extrapolated from the pediatric literature or based on retrospective reviews. A growing body of literature underscores the genetic similarities between adult and pediatric disease, which may allow tailored therapy directed towards specific molecular pathways and may have an impact on clinical outcomes. Here we present the history, staging system, and treatment of medulloblastoma, reviewing the prognostic value and clinical application of molecular subtyping while highlighting the differences between adult and pediatric disease.

Original languageEnglish (US)
JournalONCOLOGY (United States)
Volume26
Issue number11
StatePublished - Jan 1 2012

Fingerprint

Primitive Neuroectodermal Tumors
Medulloblastoma
Pediatrics
Brain Neoplasms
Population
History
Clinical Trials
Incidence
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adult medulloblastoma, from spongioblastoma cerebelli to the present day : A review of treatment and the integration of molecular markers. / Shonka, Nicole A; Brandes, Alba; de Groot, John F.

In: ONCOLOGY (United States), Vol. 26, No. 11, 01.01.2012.

Research output: Contribution to journalReview article

@article{247f2c84019e4ea491a098ced1f0f47e,
title = "Adult medulloblastoma, from spongioblastoma cerebelli to the present day: A review of treatment and the integration of molecular markers",
abstract = "Although they represent the most common malignant brain tumor in the pediatric population, medulloblastomas are rare in adults, with an incidence of 0.5 per million. With only one exception, all of the prospective clinical trials in this disease have been done in the pediatric population, and therefore therapy for adult medulloblastoma has been either extrapolated from the pediatric literature or based on retrospective reviews. A growing body of literature underscores the genetic similarities between adult and pediatric disease, which may allow tailored therapy directed towards specific molecular pathways and may have an impact on clinical outcomes. Here we present the history, staging system, and treatment of medulloblastoma, reviewing the prognostic value and clinical application of molecular subtyping while highlighting the differences between adult and pediatric disease.",
author = "Shonka, {Nicole A} and Alba Brandes and {de Groot}, {John F.}",
year = "2012",
month = "1",
day = "1",
language = "English (US)",
volume = "26",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "11",

}

TY - JOUR

T1 - Adult medulloblastoma, from spongioblastoma cerebelli to the present day

T2 - A review of treatment and the integration of molecular markers

AU - Shonka, Nicole A

AU - Brandes, Alba

AU - de Groot, John F.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Although they represent the most common malignant brain tumor in the pediatric population, medulloblastomas are rare in adults, with an incidence of 0.5 per million. With only one exception, all of the prospective clinical trials in this disease have been done in the pediatric population, and therefore therapy for adult medulloblastoma has been either extrapolated from the pediatric literature or based on retrospective reviews. A growing body of literature underscores the genetic similarities between adult and pediatric disease, which may allow tailored therapy directed towards specific molecular pathways and may have an impact on clinical outcomes. Here we present the history, staging system, and treatment of medulloblastoma, reviewing the prognostic value and clinical application of molecular subtyping while highlighting the differences between adult and pediatric disease.

AB - Although they represent the most common malignant brain tumor in the pediatric population, medulloblastomas are rare in adults, with an incidence of 0.5 per million. With only one exception, all of the prospective clinical trials in this disease have been done in the pediatric population, and therefore therapy for adult medulloblastoma has been either extrapolated from the pediatric literature or based on retrospective reviews. A growing body of literature underscores the genetic similarities between adult and pediatric disease, which may allow tailored therapy directed towards specific molecular pathways and may have an impact on clinical outcomes. Here we present the history, staging system, and treatment of medulloblastoma, reviewing the prognostic value and clinical application of molecular subtyping while highlighting the differences between adult and pediatric disease.

UR - http://www.scopus.com/inward/record.url?scp=84874636719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874636719&partnerID=8YFLogxK

M3 - Review article

VL - 26

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 11

ER -